Pregabalin Extended Release Tablet, Film Coated, Extended Release
Product Images NDC 50228-463

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Pregabalin Extended Release (NDC 50228-463). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sciegen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (50 mg/500 mg Tablet Bottle Label)

This is a medication that comes in the form of 30 extended-release tablets, each containing 165 mg of pregabalin, USP. The intended use and dosage is not provided and must be obtained from the accompanying prescribing information. It should be stored between 20°C to 23°C (68°F to 77°F), with permissible temperatures between 15°C to 30°C (between 59°F to 86°F). The medication must be kept out of the reach of children and dispensed in child-resistant containers. Each patient must be provided with the accompanying medication guide. The manufacturer is ScieGen Pharmaceuticals Inc. based in Hauppauge, NY 11788.*

FDA Label Image

Principal Display Panel (50 mg/500 mg Tablet Bottle Label)

Each tablet of Pregabalin Extended-Release contains 165mg of pregabalin USP. It is essential to dispense this medication in tight, child-resistant containers and store it between 20°C to 25°C (68°F to 77°F), with permitted excursions between 15°C to 30°C (between 59°F to 86°F). The package should include the prescribing information and medication guide to be given to each patient. This medication should always be out of the reach of children. It is manufactured by ScieGen Pharmaceuticals, Inc, with an NDC of 50228-463-05. Rev. 08/21.*

FDA Label Image

Principal Display Panel (50 mg/500 mg Tablet Bottle Label)

FDA Label Image

Principal Display Panel (50 mg/500 mg Tablet Bottle Label)

Each tablet of this medicine contains 330 mg of pregabalin, USP. It is an extended-release tablet that should be dispensed in child-resistant containers. The medicine should be stored at temperatures between 20°C to 25°C (68°F to 77°F); allowed excursions between 15°C to 30°C (between 59°F to 86°F). Please refer to the accompanying prescribing information and dispense the medication guide to each patient. The manufacturer of this medicine is ScieGen Pharmaceuticals, Inc. and their address is in Hauppauge, NY 11788.*

FDA Label Image

Principal Display Panel (50 mg/500 mg Tablet Bottle Label)

This is a medication that comes in tablet form with a dosage of 82.5 mg of pregabalin. It is important to refer to the prescribing information before usage. The tablets should be stored in a room temperature between 20°C to 25°C and can have excursions permitted between 15°C to 30°C. The medication should be discarded in tight and child-resistant containers to keep it away from children. Extended-release tablets are available in a package of 30 tablets and the medication should only be dispensed with a patient guide. It is manufactured by ScieGen Pharmaceuticals, Inc in Hauppauge, NY 11788.*

FDA Label Image

Principal Display Panel (50 mg/500 mg Tablet Bottle Label)

Each tablet contains 82.5 mg pregabalin, USP. The dosage and usage information should be obtained from the accompanying prescribing information. The tablets must be stored in a temperature-controlled location and dispensed in tight and child-resistant containers. The medication guide should be given to each patient. The brand of medication is ScieGen, and it has been manufactured by ScieGen Pharmaceuticals, Inc at their facility in Hauppauge, NY 11788. The lot and expiration dates are not available.*

FDA Label Image

Principal Display Panel (50 mg/500 mg Tablet Bottle Label)

This text provides two equations used in medicine to estimate renal function. The first equation estimates the glomerular filtration rate based on a person's age and weight, while the second equation estimates it using the person's serum creatinine levels. The second equation also includes a correction factor for female patients.*

FDA Label Image

Principal Display Panel (50 mg/500 mg Tablet Bottle Label)

This table presents the percentage of patients that improved through the use of Pregabalin versus Placebo, as well as the percentage of improvement in pain from baseline. The graph shows a significant increase in the percentage of patients improved when treated with Pregabalin versus Placebo. The percentage of improvement in pain from baseline is not specified.*

FDA Label Image

Formula (Structure 01)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.